Monika E. Hegi

47.2k total citations · 11 hit papers
155 papers, 20.8k citations indexed

About

Monika E. Hegi is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, Monika E. Hegi has authored 155 papers receiving a total of 20.8k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Genetics, 81 papers in Molecular Biology and 43 papers in Cancer Research. Recurrent topics in Monika E. Hegi's work include Glioma Diagnosis and Treatment (109 papers), Epigenetics and DNA Methylation (35 papers) and Brain Metastases and Treatment (29 papers). Monika E. Hegi is often cited by papers focused on Glioma Diagnosis and Treatment (109 papers), Epigenetics and DNA Methylation (35 papers) and Brain Metastases and Treatment (29 papers). Monika E. Hegi collaborates with scholars based in Switzerland, United States and Germany. Monika E. Hegi's co-authors include Roger Stupp, Michael Weller, Thierry Gorlia, Marie‐France Hamou, Nicolas de Tribolet, J. Gregory Cairncross, R.O. Mirimanoff, Johannes A. Hainfellner, Annie‐Claire Diserens and Martin J. van den Bent and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Monika E. Hegi

154 papers receiving 20.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

2005 5.2k citations Monika E. Hegi, Annie‐Claire Diserens et al. New England Journal of Medicine profile →
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

2012 866 citations Annika Malmström, Christine Marosi et al. profile →
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

2013 742 citations Mark R. Gilbert, Meihua Wang et al. Journal of Clinical Oncology profile →
Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

2008 658 citations Monika E. Hegi, Roger Stupp et al. Journal of Clinical Oncology profile →
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

2004 634 citations Monika E. Hegi, Pierre-Yves Dietrich et al. Clinical Cancer Research profile →
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

2020 618 citations Monika E. Hegi et al. profile →
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

2009 575 citations Michael Weller, Roger Stupp et al. profile →
Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

2008 566 citations Thierry Gorlia, Wanyu L. Lambiv et al. Journal of Clinical Oncology profile →
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

2014 445 citations Michael Weller, Monika E. Hegi et al. Neuro-Oncology profile →
MGMT testing—the challenges for biomarker-based glioma treatment

2014 393 citations Wolfgang Wick, Michael Weller et al. profile →
Glioma epigenetics: From subclassification to novel treatment options

2017 368 citations Monika E. Hegi et al. profile →

Peers

Countries citing papers authored by Monika E. Hegi

Since Specialization

Citations

This map shows the geographic impact of Monika E. Hegi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monika E. Hegi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monika E. Hegi more than expected).

Fields of papers citing papers by Monika E. Hegi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monika E. Hegi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monika E. Hegi. The network helps show where Monika E. Hegi may publish in the future.

Co-authorship network of co-authors of Monika E. Hegi

This figure shows the co-authorship network connecting the top 25 collaborators of Monika E. Hegi. A scholar is included among the top collaborators of Monika E. Hegi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monika E. Hegi. Monika E. Hegi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients 2024 ·Neuro-Oncology ·Monika E. Hegi, Felix Boakye Oppong, James Perry, Wolfgang Wick, Roger Henriksson, Normand Laperrière, Thierry Gorlia, Annika Malmström, Michael Weller	16
2	Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG 2023 ·Molecular Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Monika E. Hegi	4
3	Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline 2023 ·Neuro-Oncology ·Felix Sahm, Sebastian Brandner, Luca Bertero, David Capper, Pim J. French, Dominique Figarella‐Branger, Felice Giangaspero, Christine Haberler, Monika E. Hegi, Bjarne Winther Kristensen, (unknown), Matthias Preusser, Bastiaan B.J. Tops, Martin J. van den Bent, Wolfgang Wick, Guido Reifenberger, Pieter Wesseling	39
4	EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection 2023 ·Neuro-Oncology ·David Capper, Guido Reifenberger, Pim J. French, Leonille Schweizer, Michael Weller, Mehdi Touat, Simone P. Niclou, Philipp Euskirchen, Christine Haberler, Monika E. Hegi, Sebastian Brandner, Émilie Le Rhun, Roberta Rudà, Marc Sanson, Ghazaleh Tabatabai, Felix Sahm, Patrick Y. Wen, Pieter Wesseling, Matthias Preusser, Martin J. van den Bent	54
5	Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells 2022 ·Cancers ·(unknown), (unknown), Petra Leukel, Katrin Frauenknecht, Clemens Sommer, (unknown), Monika E. Hegi, Markus Christmann, Bernd Kaina	33
6	MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials 2018 ·Clinical Cancer Research ·Monika E. Hegi, (unknown), Thierry Gorlia, Roger Stupp, Mark R. Gilbert, Olivier Chinot, Burt Nabors, Greg Jones, Wim Van Criekinge, Josef Straub, Michael Weller	90
7	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome 2016 ·Oncotarget ·Michael Weller, Burt Nabors, Thierry Gorlia, Henning Leske, Elisabeth J. Rushing, Pierre Bady, Christine Hicking, James Perry, (unknown), Patrick Roth, Wolfgang Wick, Simon L. Goodman, Monika E. Hegi, Martin Picard, Holger Moch, Josef Straub, Roger Stupp	63
8	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial breakdown → 2013 ·Journal of Clinical Oncology ·Mark R. Gilbert, Meihua Wang, Kenneth Aldape, Roger Stupp, Monika E. Hegi, Kurt A. Jaeckle, Terri S. Armstrong, Jeffrey S. Wefel, Minhee Won, Deborah T. Blumenthal, Anita Mahajan, Christopher J. Schultz, Sara Erridge, Brigitta G. Baumert, (unknown), Tzahala Tzuk-Shina, Paul D. Brown, Arnab Chakravarti, Walter J. Curran, Minesh P. Mehta	742
9	Molecular characterization leads the way 2013 ·Nature Reviews Clinical Oncology ·Roger Stupp, Monika E. Hegi	10
10	Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial 2011 ·Molecular Cancer Therapeutics ·Monika E. Hegi, Annie‐Claire Diserens, Pierre Bady, (unknown), Mathilde C.M. Kouwenhoven, Mauro Delorenzi, Wanyu L. Lambiv, Marie‐France Hamou, Matthias S. Matter, Arend Koch, Frank L. Heppner, Yasuhiro Yonekawa, Adrian Merlo, Karl Frei, Luigi Mariani, Silvia Höfer	149
11	Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients 2011 ·Journal of Clinical Investigation ·Sameer Agnihotri, Aaron S. Gajadhar, (unknown), Thierry Gorlia, Kristin Diefes, Paul S. Mischel, Joanna Kelly, Gail McGown, Mary Thorncroft, Brett L. Carlson, Jann N. Sarkaria, Geoffrey P. Margison, Kenneth Aldape, Cynthia Hawkins, Monika E. Hegi, Abhijit Guha	137
12	Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma 2010 ·Journal of Clinical Oncology ·Roger Stupp, Monika E. Hegi, Bart Neyns, Roland Goldbrunner, Uwe Schlegel, Paul M. Clément, Gerhard G. Grabenbauer, Adrian F. Ochsenbein, Matthias Simon, Pierre-Yves Dietrich, Torsten Pietsch, Christine Hicking, Joerg-Christian Tonn, (unknown), Alessia Pica, Mirjam Hermisson, Stefan Krueger, Martin Picard, Michael Weller	341
13	Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres 2010 ·Clinical Cancer Research ·Davide Sciuscio, Annie‐Claire Diserens, (unknown), Danielle Martinet, Greg Jones, Robert-Charles Janzer, Claudio Pollo, Marie‐France Hamou, Bernd Kaina, Roger Stupp, Marc Levivier, Monika E. Hegi	68
14	Combined Lysophosphatidic Acid/Platelet-Derived Growth Factor Signaling Triggers Glioma Cell Migration in a Tenascin-C Microenvironment 2008 ·Cancer Research ·Katrin Lange, Martial Kammerer, Falk Saupe, Monika E. Hegi, Stefan Grotegut, Erika Fluri, Gertraud Orend	36
15	Endothelin Receptor Type B Counteracts Tenascin-C–Induced Endothelin Receptor Type A–Dependent Focal Adhesion and Actin Stress Fiber Disorganization 2007 ·Cancer Research ·Katrin Lange, Martial Kammerer, Monika E. Hegi, Stefan Grotegut, Antje Dittmann, Wentao Huang, Erika Fluri, George W. Yip, Martin Götte, Christian Ruiz, Gertraud Orend	56
16	Histopathologic assessment of hot‐spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors 2006 ·Cancer ·Matthias Preusser, Harald Heinzl, Ellen Gelpí, (unknown), Christine Haberler, Peter Birner, Christine Marosi, Monika E. Hegi, Thierry Gorlia, Johannes A. Hainfellner	52
17	MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma breakdown → 2005 ·New England Journal of Medicine ·Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia, Marie‐France Hamou, Nicolas de Tribolet, Michael Weller, Johan M. Kros, Johannes A. Hainfellner, Warren Mason, Luigi Mariani, Jacoline E. C. Bromberg, Peter Hau, R.O. Mirimanoff, J. Gregory Cairncross, Robert C. Janzer, Roger Stupp	5232
18	Differential Gene Expression Analysis Reveals Activation of Growth Promoting Signaling Pathways by Tenascin-C 2004 ·Cancer Research ·Christian Ruiz, Wentao Huang, Monika E. Hegi, Katrin Lange, Marie‐France Hamou, Erika Fluri, Edward J. Oakeley, Ruth Chiquet‐Ehrismann, Gertraud Orend	76
19	Recent developments in the management of maligant glioma. 2003 ·IRIS ·Roger Stupp, Monika E. Hegi	2
20	Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. 1994 ·PubMed ·Monika E. Hegi, Theodora R. Devereux, William F. Dietrich, Charles Cochran, Eric S. Lander, Julie F. Foley, (unknown), M W Anderson, Roger W. Wiseman	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact